Journal of Laboratory Medicine, 2022 The liquid profiling approach is currently at the threshold of translation from research application in various clinical trials to introduction into the management of cancer patients in the context of clinical care.
Froelich Matthias F. +3 more
doaj +1 more source
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study [PDF]
, 2018 open32Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.openKhan, Khurum; Rata,
core +1 more source
Cancer Biology & Medicine, 2021 Objective: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer.
Nanlin Hu +13 more
doaj +1 more source
Evaluation of pre-analytical factors affecting plasma DNA analysis. [PDF]
, 2018 Pre-analytical factors can significantly affect circulating cell-free DNA (cfDNA) analysis. However, there are few robust methods to rapidly assess sample quality and the impact of pre-analytical processing. To address this gap and to evaluate effects of
Berens, Michael E +15 more
core +1 more source
The rationale for liquid biopsy in colorectal cancer: focus on circulating tumor cells [PDF]
, 2015 Capturing circulating tumor cells (CTCs) and/or circulating tumor DNA from blood, which represents a precious source of biological material derived from both primary and metastatic tumors, has been named a 'liquid biopsy'. While the circulating tumor DNA
Carletti, Raffaella +6 more
core +1 more source
What information could the main actors of liquid biopsy provide? A representative case of non-small cell lung cancer (NSCLC) [PDF]
, 2018 In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect "druggable" mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells
Manicone, M. +6 more
core +1 more source
The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children : a review [PDF]
, 2020 Cell-free DNA profiling using patient blood is emerging as a non-invasive complementary technique for cancer genomic characterization. Since these liquid biopsies will soon be integrated into clinical trial protocols for pediatric cancer treatment ...
Astrahantseff, Kathy +12 more
core +2 more sources
Plasma ctDNA TP53 Mutation and Breast Cancer Prognosis: A Systematic Review and Meta-Analysis
Xiehe Yixue ZazhiObjectiveTo analyze the association between plasma circulating tumor DNA (ctDNA) TP53 mutation status and survival outcomes in breast cancer patients.MethodsPubMed, Embase, and the Cochrane Library were searched for relevant literature published between ...
FAN Hao +7 more
doaj +1 more source
The Role of ctDNA in Gastric Cancer
Cancers, 2022 Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural
Justin Mencel +3 more
openaire +3 more sources
Pan-cancer screening by circulating tumor DNA (ctDNA) – recent breakthroughs and chronic pitfalls
Journal of Laboratory Medicine, 2022 Early detection is crucial for optimal treatment and prognosis of cancer. New approaches for pan-cancer screening comprise the comprehensive characterization of circulating tumor DNA (ctDNA) in plasma by next generation sequencing and molecular profiling
Holdenrieder Stefan +3 more
doaj +1 more source